Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
Intern Med ; 61(4): 585-589, 2022 Feb 15.
Article in English | MEDLINE | ID: covidwho-1690565

ABSTRACT

With expansion of the COVID-19 pandemic, reports of post-COVID-19 interstitial lung disease (ILD) have been emerging. However, there are few reports regarding treatment. Some reports indicate that corticosteroids are effective for post-COVID-19 ILD, but the use of long-term corticosteroid carries risks of side effects. We administered tacrolimus to an elderly patient with post-COVID-19 ILD who suffered a respiratory failure relapse during steroid tapering. The respiratory status improved with tacrolimus in the post-acute phase, but pulmonary fibrosis progressed in the late phase. Tacrolimus may be effective for treating post-COVID-19 ILD in the post-acute phase, but it does not halt progression of pulmonary fibrosis.


Subject(s)
COVID-19 , Lung Diseases, Interstitial , Aged , Humans , Lung , Lung Diseases, Interstitial/epidemiology , Pandemics , SARS-CoV-2 , Tacrolimus/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL